An individual-participant meta-analysis of prospective studies found menopausal hormone therapy associated with an elevation in the risk of breast cancer, with the highest risks associated with daily combined therapy.
The Food and Drug Administration recently approved two new modalities to aid in menopause management: MenoCheck, a diagnostic tool to show a woman’s menopausal status, and Bijuva, a medication to help with hot flashes.
The U.S. Preventive Services Task Force has issued a final recommendation statement and evidence summary upholding its earlier recommendation against use of hormone therapy for the primary prevention of chronic conditions in postmenopausal women.
A higher risk of depressive symptoms has been observed in the menopausal transition period. Antidepressant medications are often recommended; however, many meta-analyses have only shown modest benefit of such medications over placebo. This study compares individual homeopathic treatment vs. placebo and the antidepressant medication fluoxetine vs. placebo for the treatment of moderate to severe depression in peri- and postmenopausal women.